Analyst Derek Archila of Wells Fargo maintained a Hold rating on Sutro Biopharma (STRO – Research Report), with a price target of $4.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Derek Archila has given his Hold rating due to a combination of factors affecting Sutro Biopharma. The company has recently decided to discontinue its investment in Luvelta, which has raised concerns about its competitiveness and differentiation from other similar products. This strategic shift towards focusing on preclinical programs indicates a reset in their approach, but it also means that there will be limited data available in the near term to drive significant investor interest.
Additionally, the company is undergoing significant restructuring, including a change in leadership and a reduction in workforce, which are aimed at extending their cash runway. Despite these efforts, the lack of immediate catalysts and the current market performance, with shares trading below cash value, suggest that there is no urgent need to invest in the stock at this time. As such, Archila maintains a cautious stance, recommending a Hold rating until more substantial progress is observed in their pipeline developments.